Company Overview - Jinhe Biology Co., Ltd. is located in Inner Mongolia and was established on March 14, 1990, with its listing date on July 13, 2012 [2] - The company specializes in the production, sales, research, and service of animal health products, with a revenue composition of 61.83% from veterinary chemical drugs, 19.76% from starch and related products, 11.12% from veterinary vaccines, 4.97% from environmental services, and 2.15% from other sources [2] Financial Performance - For the first half of 2025, Jinhe Biology achieved a revenue of 1.39 billion yuan, representing a year-on-year growth of 30.45%, and a net profit attributable to shareholders of 138 million yuan, up 51.52% year-on-year [2] - The company has distributed a total of 877 million yuan in dividends since its A-share listing, with 227 million yuan distributed over the past three years [3] Stock Performance - As of September 16, Jinhe Biology's stock price was 7.05 yuan per share, with a market capitalization of 5.44 billion yuan [1] - The stock has increased by 61.22% year-to-date, with a recent 5-day increase of 1.29%, a 20-day decrease of 5.87%, and a 60-day increase of 12.44% [1] - The company has appeared on the trading leaderboard six times this year, with the most recent occurrence on April 16, where it recorded a net buy of -28.30 million yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 104.38% to 64,500, while the average circulating shares per person decreased by 51.07% to 11,547 shares [2] - Among the top ten circulating shareholders, Guotai Zhongzheng Livestock Breeding ETF is the third-largest shareholder, holding 7.66 million shares as a new investor [3]

2025年1至6月份，金河生物的营业收入构成为：兽用化学药品占比61.83%，农产品加工业占比 19.76%，兽用生物制品占比11.12%，环保业务占比4.97%，其他占比2.15%。 （文章来源：每日经济新闻） 金河生物（SZ 002688，收盘价：7.49元）8月19日晚间发布公告称，金河生物科技股份有限公司2025年 8月18日召开第六届董事会第二十九次会议，以9票同意，0票反对，0票弃权审议通过了《关于对外投资 设立全资子公司的议案》，同意公司以自有资金投资1000万元于上海市设立全资子公司金河艾宠易（上 海）生物技术有限公司。 ...

2025年1至6月份，金河生物的营业收入构成为：兽用化学药品占比61.83%，农产品加工业占比 19.76%，兽用生物制品占比11.12%，环保业务占比4.97%，其他占比2.15%。 （文章来源：每日经济新闻） 金河生物（SZ 002688，收盘价：7.69元）8月12日晚间发布公告称，公司于近日获得由国家知识产权局 颁发的发明专利及外观设计专利证书。专利名称为"罐体圆周分布的微生物发酵厂房"。 ...

Group 1 - The core business of the company is the research, production, and sales of veterinary drugs, including veterinary biological products and chemical drugs [1] - The company completed the transfer of 48.4213% equity in Hunan Zhong'an Biological Pharmaceutical Co., Ltd. for a transaction amount of 115 million yuan, and still holds 20% equity after the transfer [1] - On July 30, the company's stock closed at 21.36 yuan, down 0.23% from the previous trading day, with a trading volume of 82,415 hands and a transaction amount of 176 million yuan [1] Group 2 - On July 30, the net outflow of main funds for the company was 10.5372 million yuan [2]

Core Viewpoint - Jinhe Biology announced the convening of its 28th meeting of the 6th Board of Directors on July 30, 2025, to review the full and summary reports of the 2025 semi-annual report [2] Revenue Composition - For the year 2024, the revenue composition of Jinhe Biology is as follows: - Veterinary chemical drugs account for 52.06% - Agricultural product processing accounts for 24.53% - Veterinary biological products account for 14.5% - Environmental protection business accounts for 6.04% - Others account for 2.54% [2]